Editorial board member Fabio Midulla (Sapienza University, Rome, Italy) chats to us about acute viral bronchiolitis, including risk factors, challenges managing the condition, risks and recent advances.
1. What are the major risk factors for acute viral bronchiolitis? (0:12)
2. What are the challenges in the management of acute viral bronchiolitis? (1:02)
3. What short- and long-term risks are associated with the condition? (1:41)
4. What have been the most important recent advances in the management of acute viral bronchiolitis? (2:21)
5. What future studies are planned? (2:59)
Speaker disclosure: Fabio Midulla has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In Paediatric Respiratory Medicine
Theresa W Guilbert, AAAAI 2023: The VOYAGE study: Impact of exacerbation history on dupilumab efficacy in children with asthma
Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]
Theresa W Guilbert, AAAAI 2023: Health and economic burden of asthma exacerbations in children
touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]
Robin Deterding, ERS 2022: Findings from the InPedILD Trial
The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!